MX2022000060A - Métodos de tratamiento del vih en pacientes pediátricos con rilpivirina. - Google Patents

Métodos de tratamiento del vih en pacientes pediátricos con rilpivirina.

Info

Publication number
MX2022000060A
MX2022000060A MX2022000060A MX2022000060A MX2022000060A MX 2022000060 A MX2022000060 A MX 2022000060A MX 2022000060 A MX2022000060 A MX 2022000060A MX 2022000060 A MX2022000060 A MX 2022000060A MX 2022000060 A MX2022000060 A MX 2022000060A
Authority
MX
Mexico
Prior art keywords
rilpivirine
methods
pediatric patients
treating hiv
pediatric
Prior art date
Application number
MX2022000060A
Other languages
English (en)
Inventor
Herta Crauwels
Simon Vanveggel
Eygen Veerle Van
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2022000060A publication Critical patent/MX2022000060A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La divulgación se refiere al uso de rilpivirina, o una sal de la misma, para tratar infección por HIV en sujetos pediátricos.
MX2022000060A 2019-07-03 2020-07-02 Métodos de tratamiento del vih en pacientes pediátricos con rilpivirina. MX2022000060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
PCT/EP2020/068734 WO2021001508A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv in pediatric patients with rilpivirine

Publications (1)

Publication Number Publication Date
MX2022000060A true MX2022000060A (es) 2022-04-18

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022000060A MX2022000060A (es) 2019-07-03 2020-07-02 Métodos de tratamiento del vih en pacientes pediátricos con rilpivirina.
MX2021015627A MX2021015627A (es) 2019-07-03 2020-07-03 Métodos de tratamiento del vih en pacientes pediátricos con rilpivirina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015627A MX2021015627A (es) 2019-07-03 2020-07-03 Métodos de tratamiento del vih en pacientes pediátricos con rilpivirina.

Country Status (13)

Country Link
US (3) US20210000823A1 (es)
EP (2) EP3993799A1 (es)
JP (2) JP2022538338A (es)
KR (2) KR20220028049A (es)
CN (2) CN114126655A (es)
AU (2) AU2020300818A1 (es)
BR (2) BR112021026916A2 (es)
CA (2) CA3144534A1 (es)
IL (1) IL289457A (es)
JO (1) JOP20210347A1 (es)
MA (2) MA56449A (es)
MX (2) MX2022000060A (es)
WO (2) WO2021001508A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
CN103491948B (zh) * 2010-11-19 2016-11-02 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
BR112019027915A2 (pt) * 2017-06-30 2020-07-14 Viiv Healthcare Company composição de carboidrato de baixo teor glicêmico disponível, composição nutricional líquida, e, uso de uma composição de carboidrato

Also Published As

Publication number Publication date
EP3993799A1 (en) 2022-05-11
AU2020300818A1 (en) 2022-03-03
IL289457A (en) 2022-02-01
WO2021001508A1 (en) 2021-01-07
EP3993800A1 (en) 2022-05-11
CN114126655A (zh) 2022-03-01
JP2022538449A (ja) 2022-09-02
MA56449A (fr) 2022-05-11
CA3144307A1 (en) 2021-01-07
US20220313693A1 (en) 2022-10-06
US20240139186A1 (en) 2024-05-02
KR20220028048A (ko) 2022-03-08
AU2020300033A1 (en) 2022-02-24
JOP20210347A1 (ar) 2023-01-30
MX2021015627A (es) 2022-04-25
CA3144534A1 (en) 2021-01-07
MA56453A (fr) 2022-05-11
US20210000823A1 (en) 2021-01-07
CN114080223A (zh) 2022-02-22
WO2021001568A1 (en) 2021-01-07
KR20220028049A (ko) 2022-03-08
JP2022538338A (ja) 2022-09-01
BR112021026916A2 (pt) 2022-05-10
BR112021026739A2 (pt) 2022-04-26

Similar Documents

Publication Publication Date Title
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
EA201391108A1 (ru) Лечение липодистрофии
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2019015211A (es) Compuestos para el tratamiento de tnbc.
PH12019500725A1 (en) Methods of treating acute kidney injury
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2021014844A (es) Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
JOP20210347A1 (ar) طرق لعلاج فيروس نقص المناعة البشرية
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
ZA202006986B (en) Dantrolene formulations and methods of their use
PH12019500103A1 (en) Use of xibornol as active agent in the treatment of viral infections
MX2020002485A (es) Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.
MX2023000732A (es) Anticuerpos anti- alfa-4-beta-7.
UA130761U (uk) Спосіб лікування ендометриту, індукованого генітальною герпесвірусною інфекцією
TR201914615A2 (tr) Fistül ve hemoroid tedavisinde kullanılmak üzere karboksiterapi kullanımı.
UA109281U (uk) Спосіб комплексного лікування аспірин-індукованої гастропатії з застосуванням гастроцитопротективної терапії у хворих на ішемічну хворобу серця
UA98398U (ru) Способ лечения ожоговой болезни и зон паранекроза
MX2018004052A (es) Metodos y sistemas para tratar fluidos y dispositivos medicos.
UA117620U (uk) Спосіб лікування оперізувального лишаю